Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis
Pranav Gupta, Etti Goyal, Jaya Devendra
Citation Information :
Gupta P, Goyal E, Devendra J. Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. Int J Adv Integ Med Sci 2016; 1 (4):139-142.
Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, bilateral inflammatory disease showing exacerbations during the spring and summer seasons, affecting young children. Present study was conducted with the aim of comparing the efficacy of cyclosporine 0.05% with olopatadine 0.1% in recalcitrant patients of VKC.
Materials and methods
A prospective randomized controlled trial was performed on 40 eyes (20 patients of recalcitrant VKC) during the period of May 2015 to September 2015. A short course of mild steroid was given for 5 days to all patients as they presented with acute exacerbation of recalcitrant VKC.
Left eye of each patient received topical cyclosporine 0.05%, which is a nonsteroidal immunomodulator, twice daily, and right eye of the same patient received olopatadine 0.1%, which has a dual action, i.e., mast cell stabilizer action as well as antihistaminic activity, twice daily for a period of 3 months. Grading of signs and symptoms was done at the time of presentation and at 2 weeks, 1 month, and 3 months interval.
Results
When compared with baseline, scores for signs and symptoms at 2 weeks reduced significantly for both cyclosporine and olopatadine. However, at 3 months, scores as regards signs and symptoms were found to be lower in cyclosporine as compared with olopatadine eyes.
Conclusion
Cyclosporine 0.05% was found to be equally effective in treating signs and symptoms as olopatadine in the early phase of the treatment. But, a significant improvement was noted in cyclosporine eyes as compared with olopatadine eyes in the late period.
How to cite this article
Goyal E, Devendra J, Gupta P. Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. Int J Adv Integ Med Sci 2016;1(4):139-142.
Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis – randomized placebo-controlled trial. Adv Clin Exp Med 2014 May-Jun;23(3):455-461.
A randomized trial of low dose mitomycin C in treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000 Feb;107:263-269.
Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006 Nov;17(7):527-532.
Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm 2013;21(1):28-33.
A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012 Sep;30(3):177-184.
Ocular complications of topical peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000 Dec;11(6):478-483.
A comparison of efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002 Oct;24(10):1561-1575.
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocarbastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Opin 2004 Dec;20(12):1953-1958.
Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic suspension (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 1999;(228):47-52.
Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Exp Ophthalmol 2006 May-Jun;34(4):347-353.
Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 2007 Oct;26(9):1035-1038.
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with oncedaily dosing. Exp Opin Drug Metab Toxicol 2008 Apr;4(4):453-461.
Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000 Jun;107(6):1157-1163.
Ocul Immunol Inflamm 1993;1(1-2):13-17.
Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond) 2001 Feb;15(Pt 1): 39-41.
Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand 2006 Jun;84(3):406-410.
Randomised controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006 Apr;90(4):461-464.
Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002 Sep;89(3):298-303.
Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991 Nov;98(11):1679-1684.
A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis. Nihon Ganka Gakkai Zasshi 2011 Jun;115(6):508-515.
Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol 2010 Mar;21(2 Pt 1):330-335.
